What is Recursion?
Recursion is at the forefront of drug discovery, employing a unique approach that integrates advanced technologies such as biology, chemistry, automation, machine learning, and engineering. The company's core mission is to revolutionize patient treatment by industrializing the drug discovery process. Central to its operations is the Recursion Operating System, which generates a vast and rapidly expanding proprietary dataset of biological and chemical information. This data is then explored using the Recursion Map, a sophisticated suite of custom software, algorithms, and machine learning tools designed to uncover biological insights without human bias.
How much funding has Recursion raised?
Recursion has raised a total of $514.5M across 10 funding rounds:
Multiple Rounds
$4.9M
Series A
$15M
Debt
$4M
Series B
$60M
Other Financing Round
$20.5M
Series C
$121M
Series D
$239M
Other Financing Round
$50M
Debt (2015): $830K, investors not publicly disclosed
Unspecified (2015): $1.5M led by National Institutes of Health
Angel/Seed (2015): $2.6M supported by Advantage Capital Partners
Series A (2016): $15M featuring Obvious Ventures, Epic Ventures, Lux Capital, AME Cloud Ventures, Data Collective, and Wild Basin Investments
Debt (2017): $4M backed by Square 1 Bank
Series B (2017): $60M with participation from Data Collective
Other Financing Round (2018): $20.5M led by Square 1 Bank
Series C (2019): $121M supported by Data Collective, Lux Capital, CRV, Menlo Ventures, Obvious Ventures, Mubadala Ventures, Intermountain Ventures, AME Cloud Ventures, Epic Ventures, Felicis Ventures, Scottish Mortgage Investment Trust PLC, Texas Tech University System, and Two Sigma Ventures
Series D (2020): $239M featuring Baillie Gifford International, Mubadala, Two Sigma Ventures, Samsara BioCapital, Laurion Capital Management, Felicis Ventures, Advantage Capital, DCVC, Intermountain Ventures, Leaps by Bayer, Casdin Capital, EPIC Ventures, Lux Capital, Obvious Ventures, and Catalio Capital Management
Other Financing Round (2023): $50M backed by NVIDIA
Key Investors in Recursion
NVIDIA
NVIDIA is a global technology company specializing in graphics processing units (GPUs), computer hardware, and artificial intelligence computing solutions, likely providing computational power and AI expertise to Recursion's drug discovery platform.
Data Collective
Data Collective (DCVC) is a venture capital firm that typically invests in companies leveraging data-intensive technologies and deep science, aligning with Recursion's data-driven approach to drug discovery.
Lux Capital
Lux Capital is a venture capital firm that invests in technology and science ventures, often focusing on areas like artificial intelligence, robotics, and biotechnology, indicating a strategic interest in Recursion's innovative model.
What's next for Recursion?
With substantial enterprise-level funding and a recent strategic investment, Recursion is well-positioned for accelerated growth and further development of its innovative drug discovery platform. The company's focus on generating and analyzing large-scale biological datasets, combined with its advanced AI-driven exploration tools, suggests a strategic push towards identifying and advancing novel therapeutic candidates. Future endeavors will likely involve expanding its research pipeline, forging strategic partnerships, and potentially scaling its operational infrastructure to meet the demands of industrializing drug discovery.
See full Recursion company page
